Hjem
Bergithe Eikeland Oftedals bilde

Bergithe Eikeland Oftedal

Forsker
  • E-postbergithe.oftedal@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Jeg er utdannet molekylærbiolog og jobber innen immunogenetikk med fokus på endokrin autoimmun sykdom. Siden disputasen min i 2012 ved Universitetet i Bergen fortsatte jeg som post-Doc i samme gruppe og hadde ett års forskningsopphold hos Professor Hamish Scott ved University of Adelaide hvor jeg jobbet med genetikk. Jeg ble så tildelt et mobilitetsstipend fra Norges Forskningsråd og jobbet to år i gruppen til Professor Georg Holländer ved University of Oxford hvor jeg arbeidet med karakterisering av utvikling av T-celler i tymus. Siden 2019 har jeg vært ansatt som seniorforsker ved KG Jebsen-senteret for autoimmune sykdommer, og jeg ble nylig tildelt det prestisjetunge Excellence Emerging Investigator-stipendet fra Novo Nordic-stiftelsen. Mitt langsiktige mål er å karakterisere genetiske og molekylære mekanismer i det adaptive immunsystemet som er avgjørende for utviklingen av tolerante T-celler og B-celler. Videre vil jeg kombinerer denne kunnskapen i multivariante sykdomsmodeller for bedre å forutsi autoimmunt vevsdestruksjon. I tillegg ønsker jeg å utvide mitt internasjonale nettverk med mulighet for langsiktige samarbeid.

2022: 

Invited speaker at European Congress of Endocrinology (ECE) 2022, 21–24 May 2022 in Milan Italy,

Invited speaer at the 20th Biennial Meeting of the European Society for Immunodeficiencies (ESID), Gothenburg, Sweden, 12-15 October, 2022.

2016:    

Invited speaker, 12th Annual Symposium on Primary Immunodeficiency Diseases, California, USA

Selected speaker at the 43rd Scandinavian Society for Immunology meeting, Turku, Finland.

       

2015

Selected speaker at The Thymus Meeting 2015, Venice, Italy

Invited speaker at the Norwegian Immunological Society annual meeting

Vitenskapelig artikkel
  • Vis forfatter(e) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience.
  • Vis forfatter(e) (2023). Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1. FEBS Letters. 1261-1274.
  • Vis forfatter(e) (2023). Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes. iScience. 17 sider.
  • Vis forfatter(e) (2023). Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. Diabetes. 59-70.
  • Vis forfatter(e) (2022). Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies. Journal of Autoimmunity. 1-?.
  • Vis forfatter(e) (2022). Extrathymic expression of Aire controls the induction of effective T<inf>H</inf>17 cell-mediated immune response to Candida albicans. Nature Immunology. 1098-1108.
  • Vis forfatter(e) (2021). Transcriptional changes in regulatory T cells from patients with autoimmune polyendocrine syndrome type 1 suggest functional impairment of lipid metabolism and gut homing. Frontiers in Immunology. 1-12.
  • Vis forfatter(e) (2021). The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease. European Journal of Endocrinology (EJE). 607-615.
  • Vis forfatter(e) (2021). The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function. Communications Biology.
  • Vis forfatter(e) (2021). Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation. Journal of Experimental Medicine (JEM).
  • Vis forfatter(e) (2021). GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nature Communications. 1-14.
  • Vis forfatter(e) (2019). Identification and characterization of rare Toll-like receptor 3 variants in patients with autoimmune Addison’s disease. Journal of translational autoimmunity.
  • Vis forfatter(e) (2019). Coexistence of congenital adrenal hyperplasia and autoimmune Addison's disease. Frontiers in Endocrinology. 1-5.
  • Vis forfatter(e) (2018). Oral microbiota in autoimmune polyendocrine syndrome type 1. Journal of Oral Microbiology. 1-10.
  • Vis forfatter(e) (2018). 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I. Clinical and Experimental Immunology. 1-5.
  • Vis forfatter(e) (2017). T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ. Journal of Autoimmunity. 24-33.
  • Vis forfatter(e) (2017). Impaired salivary gland activity in patients with autoimmune polyendocrine syndrome type I. Autoimmunity. 211-222.
  • Vis forfatter(e) (2017). Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. Journal of Pediatric Endocrinology & Metabolism (JPEM). 3546-3556.
  • Vis forfatter(e) (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
  • Vis forfatter(e) (2016). Antibodies against NALP5 and it's role in hypoparathyroidism in autoimmune polyglandular syndrome type 1. Problemy Endokrinologii. 25-30.
  • Vis forfatter(e) (2016). A variant in the BACH2 gene is associated with susceptibility to autoimmune addison's disease in humans. Journal of Clinical Endocrinology and Metabolism (JCEM). 3865-3869.
  • Vis forfatter(e) (2016). A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism (JCEM). 2975-2983.
  • Vis forfatter(e) (2015). Revealing missing human protein isoforms based on Ab initio prediction, RNA-seq and proteomics. Scientific Reports.
  • Vis forfatter(e) (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 1185-1196.
  • Vis forfatter(e) (2015). 8q13.1-q13.2 deletion associated with inferior cerebellar vermian hypoplasia and digital anomalies: A new syndrome? Pediatric Neurology. 230-234.e1.
  • Vis forfatter(e) (2014). Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. Journal of Immunology. 3880-3890.
  • Vis forfatter(e) (2014). ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism (JCEM). E1784-E1792.
  • Vis forfatter(e) (2014). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clinical Immunology. 220-227.
  • Vis forfatter(e) (2013). Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. Journal of Clinical Immunology. 1341-1348.
  • Vis forfatter(e) (2012). Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. Journal of Clinical Immunology. 230-237.
  • Vis forfatter(e) (2011). Measuring autoantibodies against IL-17F and IL-22 in Autoimmune Polyendocrine Syndrome Type I by radioligand binding assay using fusion proteins. Scandinavian Journal of Immunology. 327-333.
  • Vis forfatter(e) (2010). Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scandinavian Journal of Immunology. 459-467.
  • Vis forfatter(e) (2008). Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clinical Immunology. 163-169.
  • Vis forfatter(e) (2008). AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes and Immunity. 130-136.
  • Vis forfatter(e) (2005). Ligand-dependent protein interactions of the estrogen receptors using the yeast two-hybrid system. Annals of the New York Academy of Sciences. 420-425.
Mastergradsoppgave
  • Vis forfatter(e) (2005). Exploring protein-protein interactions between ligand activated transcription factors using the yeast two-hybrid system.
Doktorgradsavhandling
  • Vis forfatter(e) (2019). Exploring and redefining Autoimmune polyendocrine syndrome type 1.
  • Vis forfatter(e) (2012). Autoimmune polyendocrine syndrome type I –novel diagnostic assays and immune regulation.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2019). The Natural History of APS1. 7 sider.
  • Vis forfatter(e) (2019). Aire Mutations and Autoimmune Diseases. 24 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2013). Dominant Inheritance in Autoimmune Endocrine Syndrome Type 1. Scandinavian Journal of Immunology. 306-307.
  • Vis forfatter(e) (2012). Deviant expression of defensins in sera and saliva of patients with autoimmune polyendocrine syndrome type I. Immunology. 211-212.
  • Vis forfatter(e) (2010). Nucleoporin 62, a Novel Autoantigen in Patients with Autoimmune Polyendocrine Syndrome Type I (APS I). Scandinavian Journal of Immunology. 493-494.
Poster
  • Vis forfatter(e) (2013). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with APS-1.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2021). B cells and autoantibodies in aire deficiency. Biomedicines. 1-15.
  • Vis forfatter(e) (2020). The prospects of single-cell analysis in autoimmunity. Scandinavian Journal of Immunology. 1-15.
  • Vis forfatter(e) (2020). New ERA of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology. 1-23.
  • Vis forfatter(e) (2016). AIRE-mutations and autoimmune disease. Current Opinion in Immunology. 8-15.

Se fullstendig oversikt over publikasjoner i CRIStin.

Utvalgte publikasjoner:

2021:

Transcriptional Changes in Regulatory T Cells From Patients With Autoimmune Polyendocrine Syndrome Type 1 Suggest Functional Impairment of Lipid Metabolism and Gut Homing.

Berger AH, Bratland E, Sjøgren T, Heimli M, Tyssedal T, Bruserud Ø, Johansson S, Husebye ES, Oftedal BE, Wolff ASB.

Front Immunol. 2021 Aug 30;12:722860. doi: 10.3389/fimmu.2021.722860. eCollection 2021.

 

Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation

Yael Goldfarb, Tal Givony, Noam Kadouri, Jan Dobeš, Cristina Peligero-Cruz, Itay Zalayat, Golda Damari, Bareket Dassa, Shifra Ben-Dor, Yael Gruper, Bergithe E Oftedal, Eirik Bratland, Martina M Erichsen, Amund Berger, Ayelet Avin, Shir Nevo, Uku Haljasorg, Yael Kuperman, Adi Ulman, Rebecca Haffner-Krausz, Ziv Porat, Ulus Atasoy, Dena Leshkowitz, Eystein S Husebye, Jakub Abramson

J Exp Med. 2021 Nov 1;218(11):e20201076. doi: 10.1084/jem.20201076. Epub 2021 Sep 3.

 

The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function

Bergithe E Oftedal, Stefano Maio, Adam Handel, Madeleine PJ White, Duncan Howie, Simon Davis, Nicolas Prevot, Ioanna A. Rota, Mary E Deadman, Benedikt M Kessler, Roman Fischer, Nikolaus S Trede, Erdinc Sezgin, Rick M Maizels, Georg A Holländer

Nature Communications Biology, Commun Biol 4, 681 (2021). https://doi.org/10.1038/s42003-021-02203-0

 

The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease

Anette Boe Wolff, Lars Breivik, Karl Ove Hufthammer, Marianne Aardal Grytaas, Eirik Bratland, Eystein Sverre Husebye, and Bergithe Eikeland Oftedal

DOI: https://doi.org/10.1530/EJE-20-1268, Volume/Issue: Volume 184: Issue 4, Page Range: 607–615

 

2020:

GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility.

D Eriksson, EC Røyrvik, M Aranda-Guillén, AH Berger, N Landegren, HA Alvarez, Å Hallgren, M Grytaas, S Ström, E Bratland, I Botusan, BE Oftedal ,…, S Johansson, O Kämpe, ES Husebye.

Nat Commun. 2021 Feb 11;12(1):959. doi: 10.1038/s41467-021-21015-8.

 

2019:

Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease.

Aslaksen S, Methlie P, Vigeland MD, Jøssang DE, Wolff AB, Sheng Y, Oftedal BE, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

Front Endocrinol (Lausanne). 2019 Sep 27;10:648. doi: 10.3389/fendo.2019.00648.

 

Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease.

Aslaksen S, Wolff AB, Vigeland MD, Breivik L, Sheng Y, Oftedal BE, Artaza H, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

J Transl Autoimmun. 2019 May 28;1:100005. doi: 10.1016/j.jtauto.2019.100005.

 

2018

21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I.

Berglund A, Cleemann L, Oftedal BE, Holm K, Husebye ES, Gravholt CH.

Clin Exp Immunol. 2018 Oct 29. doi: 10.1111/cei.13231. PMID: 30372540

 

Oral microbiota in autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Siddiqui H, Marthinussen MC, Chen T, Jonsson R, Oftedal BE, Olsen I, Husebye ES, Wolff AB.

J Oral Microbiol. 2018 Feb 26;10(1):1442986. doi: 10.1080/20002297.2018.1442986. PMID: 29503707

 

2017

Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune

Polyendocrine Syndrome Type 1.

Bruserud Ø, Bratland E, Hellesen A, Delaleu N, Reikvam H, Oftedal BE, Wolff ASB.

Front Immunol. 2017 Sep 1;8:1074. doi: 10.3389/fimmu.2017.01074. eCollection 2017.

PMID: 28919897

 

Salivary gland dysfunction in patients with autoimmune polyendocrine syndrome type I

Bergithe E. Oftedal, Mihaela Cuida, Martina M. Erichsen, Maria Tveiterås, Anja Østre, Daniel Hammenfors, Malin Johnsson, Kai Kisand, Reinhild Klein, Roland Jonsson, Anette S. B. Wolff..

Autoimmunity. 2017 Jun;50(4):211-222. doi: 10.1080/08916934.2017.1344972. Epub 2017 Jul 7. PMID: 28686485

 

Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type-1. Elizaveta M. Orlova, Leila S. Sozaeva, Maria A. Kareva, Bergithe E. Oftedal, Anette S.B. Wolff, Lars Breivik, Ekaterina Y. Zakharova, Olle Kämpe, Per M. Knappskog, Valentina A. Peterkova, Eystein S. Husebye. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3546-3556. doi: 10.1210/jc.2017-00139. PMID: 28911151

 

T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ

Oftedal, B.E., Lundgren, B.A., Hamm, D., Finstermeier, K., Gan, P.Y., Holdsworth, S.R., Hahn, C.N., Schreiber, A.W., and Scott, H.S.

J Autoimmun. 2017 Mar 15. pii: S0896-8411(16)30344-4. doi: 10.1016/j.jaut.2017.03.002. [Epub ahead of print]. PMID: 28318808

 

2016:

A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans

Pazderska A, Oftedal BE, Napier CM, Ainsworth HF, Husebye ES, Cordell HJ, Pearce SH, Mitchell AL.

J Clin Endocrinol Metab. 2016 Nov;101(11):3865-3869. Epub 2016 Sep 28. PMID: 27680876

 

A longitudinal follow-up of Autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Oftedal BE, Landegren N, Erichsen M, Bratland E, Lima K, Jørgensen AP, Myhre AG, Svartberg J, Fougner KJ, Bakke Å, Nedrebø BG, Mella B, Breivik L, Viken MK, Knappskog PM, Marthinussen MC, Løvås K, Kämpe O, Wolff AB, Husebye ES.

J Clin Endocrinol Metab. 2016 Jun 2:jc20161821. [Epub ahead of print] PMID: 27253668

 

2015:

Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases

Bergithe E. Oftedal, Alexander Hellesen, Martina Moter Erichsen, Eirik Bratland, Ayelet Vardi, Jaakko Perheentupa, E. Helen Kemp, Torunn Fiskerstrand, Marte K. Viken, Anthony P. Weetman, Sarel J. Fleishman, Siddharth Banka, William G. Newman, W.A.C Sewell, Leila S. Sozaeva, Tetyana Zayats, Kristoffer Haugarvoll, Elizaveta M. Orlova, Jan Haavik, Stefan Johansson, Per M. Knappskog, Kristian Løvås, Anette S. B. Wolff, Jakub Abramson, Eystein S. Husebye

Immunity. 2015 Jun 16;42(6):1185-96. doi: 10.1016/j.immuni.2015.04.021. PMID: 26084028

Citations: 54 (webofknowledge.com)

Impact factor: 24.1

2022-2027           “21-Hydroxylase reactive B cells and their immunotherapeutic potential in autoimmune Addison’s disease”. Funded by the Novo Nordic Fundation. 10 000 000 DKK. Oftedal is the project leader.

2021-2024           “Will B-cell tell the tales? Autoimmune B cells in autoimmune Addison’s disease”. Funded by the Regional Health Authorities. 3 000 000 NOK, Oftedal is the project leader.

2017-2021          “KG Jebsen center for autoimmune disorders”. A national centre established in Bergen, where Oftedal is a principal investigator. Funded by KG Jebsen, 18 000 000.

2017-2020          “Identification of novel monogenic autoimmune syndromes”. Partners are Husebye, Bratland and Wolff. Funded by Norwegian Research Council, 4 000 000 NOK.

2016-2019          “New perspectives on regulation of peripheral tissue antigen expression within the thymus”. Oftedal is the project leader. Partners are Georg Holländer and Eystein Husebye. Funded by the Norwegian Research Council. 3 328 000 NOK

 

Normal 0 false false false EN-GB X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-fareast-language:EN-US;}